The urokinase receptor: Focused cell surface proteolysis, cell adhesion and signaling

FEBS Letters

Volumn 584, Issue 9, 2010, Pages 1923-1930

  Blasi, Francesco ^a,b   Sidenius, Nicolai ^b  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

Author keywords

Cell adhesion; Cell migration; Cell proliferation; Signaling; Urokinase receptor uPAR

Indexed keywords

INTEGRIN; UROKINASE RECEPTOR; VITRONECTIN; MEMBRANE PROTEIN;

CARCINOGENESIS; CELL ADHESION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL SURFACE; CELLULAR DISTRIBUTION; CHRONIC INFLAMMATION; EXTRACELLULAR MATRIX; HUMAN; INFLAMMATION; INTERNALIZATION; NEOPLASM; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS; REVIEW; SIGNAL TRANSDUCTION; STEM CELL MOBILIZATION; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; CONFORMATION; METABOLISM; PHYSIOLOGY; PROTEIN BINDING; PROTEIN PROCESSING;

ANIMALS; CELL ADHESION; HUMANS; MEMBRANE GLYCOPROTEINS; MEMBRANE PROTEINS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; PROTEIN BINDING; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; SIGNAL TRANSDUCTION;

EID: 77951883821     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.febslet.2009.12.039     Document Type: Review

References (122)

1. Vassalli J.D., Baccino D., Belin D. A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase. J. Cell Biol. 1985, 100:86-92.
2. Stoppelli M.P., Corti A., Soffientini A., Cassani G., Blasi F., Associan R.K. Differentiation-enhanced binding of the aminoterminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes. PNAS 1985, 82:4939-4943.
3. Nielsen L.S., Kellerman G.M., Behrendt N., Picone R., Dan K., Blasi F. A 55,000-60,000 Mr receptor protein for urokinase-type plasminogen activator. Identification in human tumor cell lines and partial purification. J. Biol. Chem. 1988, 263:2358-2363.
4. Roldan A.L., Cubellis M.V., Masucci M.T., Behrendt N., Lund L.R., Danø K., Appella E., Blasi F. Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. EMBO J. 1990, 9:467-474. (published erratum appears in EMBO J. 9 (5) (1990) 1674).
5. Ploug M., Rønne E., Behrendt N., Jensen A.L., Blasi F., Danø K. Cellular receptor for urokinase plasminogen activator. Carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol. J. Biol. Chem. 1991, 266:1926-1933.
6. Ploug M., Ellis V. Structure-function relationships in the receptor for urokinase-type plasminogen activator. Comparison to other members of the Ly-6 family and snake venom alpha-neurotoxins. FEBS Lett. 1994, 349:163-168.
7. Ploug M. Structure-function relationships in the interaction between the urokinase-type plasminogen activator and its receptor. Curr. Pharm. Des. 2003, 9:1499-1528.
8. Kjaergaard M., Hansen L.V., Jacobsen B., Gardsvoll H., Ploug M. Structure and ligand interactions of the urokinase receptor (uPAR). Front. Biosci. 2008, 13:5441-5461.
9. Bianchi E., Ferrero E., Fazioli F., Mangili F., Wang J., Bender J.R., Blasi F., Pardi R. Integrin-dependent induction of functional urokinase receptors in primary T lymphocytes. J. Clin. Invest. 1996, 98:1133-1141.
10. Lund L.R., Eriksen J., Ralfkiaer E., Rømer J. Differential expression of urokinase-type plasminogen activator, its receptor, and inhibitors in mouse skin after exposure to a tumor-promoting phorbol ester. J. Invest. Dermatol. 1996, 106:622-630.
11. Solberg H., Ploug M., Hoyer-Hansen G., Nielsen B.S., Lund L.R. The murine receptor for urokinase-type plasminogen activator is primarily expressed in tissues actively undergoing remodeling. J. Histochem. Cytochem. 2001, 49:237-246.
12. Marschall C., et al. UVB increases urokinase-type plasminogen activator receptor (uPAR) expression. J. Invest. Dermatol. 1999, 113:69-76.
13. Pyke C., Ralfkiaer E., Rønne E., Høyer-Hansen G., Kirkeby L., Danø K. Immunohistochemical detection of the receptor for urokinase plasminogen activator in human colon cancer. Histopathology 1994, 24:131-138.
14. Lengyel E., Wang H., Stepp E., Juarez J., Wang Y., Doe W., Pfarr C.M., Boyd D. Requirement of an upstream AP-1 motif for the constitutive and phorbol ester-inducible expression of the urokinase-type plasminogen activator receptor gene. J. Biol. Chem. 1996, 271:23176-23184.
15. Hapke S., et al. Beta(3)A-integrin downregulates the urokinase-type plasminogen activator receptor (u-PAR) through a PEA3/ets transcriptional silencing element in the u-PAR promoter. Mol. Cell. Biol. 2001, 21:2118-2132.
16. Schewe D.M., Biller T., Maurer G., Asangani I.A., Leupold J.H., Lengyel E.R., Post S., Allgayer H. Combination analysis of activator protein-1 family members, Sp1 and an activator protein-2alpha-related factor binding to different regions of the urokinase receptor gene in resected colorectal cancers. Clin. Cancer Res. 2005, 11:8538-8548.
17. Schewe D.M., et al. Tumor-specific transcription factor binding to an activator protein-2/Sp1 element of the urokinase-type plasminogen activator receptor promoter in a first large series of resected gastrointestinal cancers. Clin. Cancer Res. 2003, 9:2267-2276.
18. Lund L.R., Ellis V., Rønne E., Pyke C., Danø K. Transcriptional and post-transcriptional regulation of the receptor for urokinase-type plasminogen activator by cytokines and tumour promoters in the human lung carcinoma cell line A549. Biochem. J. 1995, 310:345-352.
19. Wang G.J., Collinge M., Blasi F., Pardi R., Bender J.R. Posttranscriptional regulation of urokinase plasminogen activator receptor messenger RNA levels by leukocyte integrin engagement. Proc. Natl. Acad. Sci. USA 1998, 95:6296-6301.
20. Shetty S., Kumar A., Idell S. Posttranscriptional regulation of urokinase receptor mRNA: identification of a novel urokinase receptor mRNA binding protein in human mesothelioma cells. Mol. Cell. Biol. 1997, 17:1075-1083.
21. Shetty S., Idell S. Urokinase receptor mRNA stability involves tyrosine phosphorylation in lung epithelial cells. Am. J. Respir. Cell. Mol. Biol. 2004, 30:69-75.
22. Sasayama T., Nishihara M., Kondoh T., Hosoda K., Kohmura E. MicroRNA-10b is overexpressed in malignant glioma and associated with tumor invasive factors, uPAR and RhoC. Int. J. Cancer 2009, 125:1407-1413.
23. Plesner T., et al. The receptor for urokinase-type plasminogen activator and urokinase is translocated from two distinct intracellular compartments to the plasma membrane on stimulation of human neutrophils. Blood 1994, 83:808-815.
24. Min H.Y., Semnani R., Mizukami I.F., Watt K., Todd R.F., Liu D.Y. CDNA for Mo3, a monocyte activation antigen, encodes the human receptor for urokinase plasminogen activator. J. Immunol. 1992, 148:3636-3642.
25. Nykjaer A., Moller B., Todd R.F., Christensen T., Andreasen P.A., Gliemann J., Petersen C.M. Urokinase receptor. An activation antigen in human T lymphocytes. J. Immunol. 1994, 152:505-516.
26. Tjwa M., et al. Membrane-anchored uPAR regulates the proliferation, marrow pool size, engraftment, and mobilization of mouse hematopoietic stem/progenitor cells. J. Clin. Invest. 2009, 119:1008-1018.
27. Sidenius N., Blasi F. The urokinase plasminogen activator system in cancer: recent advances and implications for prognosis and therapy. Cancer Metast. Rev. 2003, 22:205-222.
28. Rasch M.G., Lund I.K., Almasi C.E., Hoyer-Hansen G. Intact and cleaved uPAR forms: diagnostic and prognostic value in cancer. Front. Biosci. 2008, 13:6752-6762.
29. Blasi F., Carmeliet P. UPAR: a versatile signalling orchestrator. Nat. Rev. Mol. Cell. Biol. 2002, 3:932-943.
30. Zannetti A., et al. Coordinate up-regulation of Sp1 DNA-binding activity and urokinase receptor expression in breast carcinoma. Cancer Res. 2000, 60:1546-1551.
31. Meng S., et al. UPAR and HER-2 gene status in individual breast cancer cells from blood and tissues. Proc. Natl. Acad. Sci. USA 2006, 103:17361-17365.
32. Hildenbrand R., Niedergethmann M., Marx A., Belharazem D., Allgayer H., Schleger C., Strobel P. Amplification of the urokinase-type plasminogen activator receptor (uPAR) gene in ductal pancreatic carcinomas identifies a clinically high-risk group. J. Am. Pathol. 2009, 174:2246-2253.
33. Ellis V., Pyke C., Eriksen J., Solberg H., Dano K. The urokinase receptor: involvement in cell surface proteolysis and cancer invasion. Ann. N.Y. Acad. Sci. 1992, 667:13-31.
34. Cubellis M.V., Wun T.C., Blasi F. Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1. EMBO J. 1990, 9:1079-1085.
35. Conese M., Olson D., Blasi F. Protease nexin-1-urokinase complexes are internalized and degraded through a mechanism that requires both urokinase receptor and alpha 2-macroglobulin receptor. J. Biol. Chem. 1994, 269:17886-17892.
36. Nykjaer A., et al. Purified alpha 2-macroglobulin receptor/LDL receptor-related protein binds urokinase plasminogen activator inhibitor type-1 complex. Evidence that the alpha 2-macroglobulin receptor mediates cellular degradation of urokinase receptor-bound complexes. J. Biol. Chem. 1992, 267:14543-14546.
37. Blasi F., Vassalli J.D., Danø K. Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors. J. Cell Biol. 1987, 104:801-804.
38. Gyetko M.R., Todd R.F., Wilkinson C.C., Sitrin R.G. The urokinase receptor is required for human monocyte chemotaxis in vitro. J. Clin. Invest. 1994, 93:1380-1387.
39. Xue W., Mizukami I., Todd R.F., Petty H.R. Urokinase-type plasminogen activator receptors associate with beta1 and beta3 integrins of fibrosarcoma cells: dependence on extracellular matrix components. Cancer Res. 1997, 57:1682-1689.
40. Yebra M., Parry G.C.N., Strömblad S., Mackman N., Rosenberg S., Mueller B.M., Cheresh D.A. Requirement of receptor-bound urokinase-type plasminogen activator for integrin alphavbeta5-directed cell migration. J. Biol. Chem. 1996, 271:29393-29399.
41. Nguyen D.H., Hussaini I.M., Gonias S.L. Binding of urokinase-type plasminogen activator to its receptor in MCF-7 cells activates extracellular signal-regulated kinase 1 and 2 which is required for increased cellular motility. J. Biol. Chem. 1998, 273:8502-8507.
42. Degryse B., Resnati M., Rabbani S.A., Villa A., Fazioli F., Blasi F. Src-dependence and pertussis-toxin sensitivity of urokinase receptor-dependent chemotaxis and cytoskeleton reorganization in rat smooth muscle cells. Blood 1999, 94:1-15.
43. Resnati M., Guttinger M., Valcamonica S., Sidenius N., Blasi F., Fazioli F. Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect. EMBO J. 1996, 15:1572-1582.
44. Resnati M., Pallavicini I., Wang J.M., Oppenheim J., Serhan C.N., Romano M., Blasi F. The fibrinolytic receptor for urokinase activates the G protein-coupled chemotactic receptor FPRL1/LXA4R. Proc. Natl. Acad. Sci. USA 2002, 99:1359-1364.
45. Fazioli F., Resnati M., Sidenius N., Higashimoto Y., Appella E., Blasi F. A urokinase-sensitive region of the human urokinase receptor is responsible for its chemotactic activity. EMBO J. 1997, 16:7279-7286.
46. Selleri C., et al. In vivo activity of the cleaved form of soluble urokinase receptor: a new hematopoietic stem/progenitor cell mobilizer. Cancer Res. 2006, 66:10885-10890.
47. Kjøller L., Hall A. Rac mediates cytoskeletal rearrangements and increased cell motility induced by urokinase-type plasminogen activator receptor binding to vitronectin. J. Cell Biol. 2001, 152:1145-1157.
48. Madsen C.D., Ferraris G.M., Andolfo A., Cunningham O., Sidenius N. UPAR-induced cell adhesion and migration: vitronectin provides the key. J. Cell Biol. 2007, 177:927-939.
49. Smith H.W., Marra P., Marshall C.J. UPAR promotes formation of the p130Cas-Crk complex to activate Rac through DOCK180. J. Cell Biol. 2008, 182:777-790.
50. Liu D., Ghiso J.A., Estrada Y., Ossowski L. EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma. Cancer Cell 2002, 1:445-457.
51. Hoyer-Hansen G., Lund I.K. Urokinase receptor variants in tissue and body fluids. Adv. Clin. Chem. 2007, 44:65-102.
52. Kook Y.H., Adamski J., Zelent A., Ossowski L. The effect of antisense inhibition of urokinase receptor in human squamous cell carcinoma on malignancy. EMBO J. 1994, 13:3983-3991.
53. Yu W., Kim J., Ossowski L. Reduction in surface urokinase receptor forces malignant cells into a protracted state of dormancy. J. Cell Biol. 1997, 137:767-777.
54. D'Alessio S., Gerasi L., Blasi F. UPAR-deficient mouse keratinocytes fail to produce EGFR-dependent laminin-5, affecting migration in vivo and in vitro. J. Cell Sci. 2008, 121:3922-3932.
55. Mazzieri R., D'Alessio S., Kenmoe R.K., Ossowski L., Blasi F. An uncleavable uPAR mutant allows dissection of signaling pathways in uPA-dependent cell migration. Mol. Biol. Cell 2006, 17:367-378.
56. Sidenius N., Sier C.F.M., Blasi F. Shedding and cleavage of the urokinase receptor (uPAR): identification and characterisation of uPAR fragments in vitro and in vivo. FEBS Lett. 2000, 475:52-56.
57. Sier C.F., et al. Metabolism of tumour-derived urokinase receptor and receptor fragments in cancer patients and xenografted mice. Thromb. Haemost. 2004, 91:403-411.
58. Wilhelm O.G., et al. Cellular glycosylphosphatidylinositol-specific phospholipase D regulates urokinase receptor shedding and cell surface expression. J. Cell Physiol. 1999, 180:225-235.
59. Beaufort N., Leduc D., Rousselle J.C., Magdolen V., Luther T., Namane A., Chignard M., Pidard D. Proteolytic regulation of the urokinase receptor/CD87 on monocytic cells by neutrophil elastase and cathepsin G. J. Immunol. 2004, 172:540-549.
60. Beaufort N., Debela M., Creutzburg S., Kellermann J., Bode W., Schmitt M., Pidard D., Magdolen V. Interplay of human tissue kallikrein 4 (hK4) with the plasminogen activation system: hK4 regulates the structure and functions of the urokinase-type plasminogen activator receptor (uPAR). Biol. Chem. 2006, 387:217-222.
61. Leduc D., Beaufort N., de Bentzmann S., Rousselle J.C., Namane A., Chignard M., Pidard D. The Pseudomonas aeruginosa LasB metalloproteinase regulates the human urokinase-type plasminogen activator receptor through domain-specific endoproteolysis. Infect. Immun. 2007, 75:3848-3858.
62. Simon D.I., et al. Identification of a urokinase receptor-integrin interaction site. Promiscuous regulator of integrin function. J. Biol. Chem. 2000, 275:10228-10234.
63. Montuori N., Ragno P. Multiple activities of a multifaceted receptor: roles of cleaved and soluble uPAR. Front. Biosci. 2009, 14:2494-2503.
64. Høyer-Hansen G., Rønne E., Solberg H., Behrendt N., Ploug M., Lund L.R., Ellis V., Danø K. Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain. J. Biol. Chem. 1992, 267:18224-18229.
65. Koolwijk P., Sidenius N., Peters E., Sier C.F., Hanemaaijer R., Blasi F., van Hinsbergh V.W. Proteolysis of the urokinase-type plasminogen activator receptor by metalloproteinase-12: implication for angiogenesis in fibrin matrices. Blood 2001, 97:3123-3131.
66. Andolfo A., English W.R., Resnati M., Murphy G., Blasi F., Sidenius N. Metalloproteases cleave the urokinase-type plasminogen activator receptor in the D1-D2 linker region and expose epitopes not present in the intact soluble receptor. Thromb. Haemost. 2002, 88:298-306.
67. Høyer-Hansen G., Ploug M., Behrendt N., Rønne E., Danø K. Cell-surface acceleration of urokinase-catalyzed receptor cleavage. Eur. J. Biochem. 1997, 243:21-26.
68. Høyer-Hansen G., Pessara U., Holm A., Pass J., Weidle U., Danø K., Behrendt N. Urokinase-catalysed cleavage of the urokinase receptor requires an intact glycolipid anchor. Biochem. J. 2001, 358:673-679.
69. Cunningham O., Andolfo A., Santovito M.L., Iuzzolino L., Blasi F., Sidenius N. Dimerization controls the lipid raft partitioning of uPAR/CD87 and regulates its biological functions. EMBO J. 2003, 22:5994-6003.
70. Madsen C.D., Sidenius N. The interaction between urokinase receptor and vitronectin in cell adhesion and signalling. Eur. J. Cell Biol. 2008, 87:617-629.
71. Ragno P. The urokinase receptor: a ligand or a receptor? Story of a sociable molecule. Cell. Mol. Life Sci. 2006, 63:1028-1037.
72. Tang C.H., Wei Y. The urokinase receptor and integrins in cancer progression. Cell. Mol. Life Sci. 2008, 65:1916-1932.
73. Kiyan J., Kiyan R., Haller H., Dumler I. Urokinase-induced signaling in human vascular smooth muscle cells is mediated by PDGFR-beta. EMBO J. 2005, 24:1787-1797.
74. Jo M., Thomas K.S., Takimoto S., Gaultier A., Hsieh E.H., Lester R.D., Gonias S.L. Urokinase receptor primes cells to proliferate in response to epidermal growth factor. Oncogene 2007, 26:2585-2594.
75. Kugler M.C., Wei Y., Chapman H.A. Urokinase receptor and integrin interactions. Curr. Pharm. Des. 2003, 9:1565-1574.
76. Wei Y., Yang X., Liu Q., Wilkins J.A., Chapman H.A. A role for caveolin and the urokinase receptor in integrin-mediated adhesion and signaling. J. Cell Biol. 1999, 144:1285-1294.
77. Czekay R.P., Kuemmel T.A., Orlando R.A., Farquhar M.G. Direct binding of occupied urokinase receptor (uPAR) to LDL receptor-related protein is required for endocytosis of uPAR and regulation of cell surface urokinase activity. Mol. Biol. Cell 2001, 12:1467-1479.
78. Li Y., Knisely J.M., Lu W., McCormick L.M., Wang J., Henkin J., Schwartz A.L., Bu G. LDL receptor-related protein 1B impairs urokinase receptor regeneration on the cell surface and inhibits cell migration. J. Biol. Chem. 2002, 22:22.
79. Selleri C., et al. Involvement of the urokinase-type plasminogen activator receptor in hematopoietic stem cell mobilization. Blood 2005, 105:2198-2205.
80. Nykjaer A., et al. Mannose 6-phosphate/insulin-like growth factor-II receptor targets the urokinase receptor to lysosomes via a novel binding interaction. J. Cell Biol. 1998, 141:815-828.
81. Behrendt N., Jensen O.N., Engelholm L.H., Mortz E., Mann M., Dano K. A urokinase receptor-associated protein with specific collagen binding properties. J. Biol. Chem. 2000, 275:1993-2002.
82. Llinas P., Helene Le Du M., Gardsvoll H., Dano K., Ploug M., Gilquin B., Stura E.A., Menez A. Crystal structure of the human urokinase plasminogen activator receptor bound to an antagonist peptide. EMBO J. 2005, 24:1656-1663.
83. Huai Q., et al. Structure of human urokinase plasminogen activator in complex with its receptor. Science 2006, 311:656-659.
84. Barinka C., et al. Structural basis of interaction between urokinase-type plasminogen activator and its receptor. J. Mol. Biol. 2006, 363:482-495.
85. Appella E., Blasi F. The growth factor module of urokinase is the binding sequence for its receptor. Ann. N.Y. Acad. Sci. 1987, 511:192-195.
86. Behrendt N., Ploug M., Patthy L., Houen G., Blasi F., Danø K. The ligand-binding domain of the cell surface receptor for urokinase-type plasminogen activator. J. Biol. Chem. 1991, 266:7842-7847.
87. Gardsvoll H., Gilquin B., Ledu M.H., Menez A., Jorgensen T.J., Ploug M. Characterization of the functional epitope on the urokinase receptor. Complete alanine scanning mutagenesis supplemented by chemical crosslinking. J. Biol. Chem. 2006, 281:19260-19272.
88. Picone R., et al. Regulation of urokinase receptors in monocytelike U937 cells by phorbol ester phorbol myristate acetate. J. Cell Biol. 1989, 108:693-702.
89. Gardsvoll H., Werner F., Sondergaard L., Dano K., Ploug M. Characterization of low-glycosylated forms of soluble human urokinase receptor expressed in Drosophila Schneider 2 cells after deletion of glycosylation-sites. Protein Expr. Purif. 2004, 34:284-295.
90. Bass R., Ellis V. Regulation of urokinase receptor function and pericellular proteolysis by the integrin alpha(5)beta(1). Thromb. Haemost. 2009, 101:954-962.
91. Waltz D.A., Sailor L.Z., Chapman H.A. Cytokines induce urokinase-dependent adhesion of human myeloid cells. J. Clin. Invest. 1993, 91:1541-1552.
92. Waltz D.A., Chapman H.A. Reversible cellular adhesion to vitronectin linked to urokinase receptor occupancy. J. Biol. Chem. 1994, 269:14746-14750.
93. Wei Y., Waltz D.A., Rao N., Drummond R.J., Rosenberg S., Chapman H.A. Identification of the urokinase receptor as an adhesion receptor for vitronectin. J. Biol. Chem. 1994, 269:32380-32388.
94. Huai Q., et al. Crystal structures of two human vitronectin, urokinase and urokinase receptor complexes. Nat. Struct. Mol. Biol. 2008, 15:422-423.
95. Gardsvoll H., Ploug M. Mapping of the vitronectin-binding site on the urokinase receptor: involvement of a coherent receptor interface consisting of residues from both domain I and the flanking interdomain linker region. J. Biol. Chem. 2007, 282:13561-13572.
96. Li Y., Lawrence D.A., Zhang L. Sequences within domain II of the urokinase receptor critical for differential ligand recognition. J. Biol. Chem. 2003, 278:29925-29932.
97. Waltz D.A., Natkin L.R., Fujita R.M., Wei Y., Chapman H.A. Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin. J. Clin. Invest. 1997, 100:58-67.
98. Hillig T., et al. A composite role of vitronectin and urokinase in the modulation of cell morphology upon expression of the urokinase receptor. J. Biol. Chem. 2008, 283:15217-15223.
99. Deng G., Curriden S.A., Wang S., Rosenberg S., Loskutoff D.J. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release?. J. Cell Biol. 1996, 134:1563-1571.
100. Okumura Y., Kamikubo Y., Curriden S.A., Wang J., Kiwada T., Futaki S., Kitagawa K., Loskutoff D.J. Kinetic analysis of the interaction between vitronectin and the urokinase receptor. J. Biol. Chem. 2002, 277:9395-9404.
101. Høyer-Hansen G., Behrendt N., Ploug M., Danø K., Preissner K.T. The intact urokinase receptor is required for efficient vitronectin binding: receptor cleavage prevents ligand interaction. FEBS Lett. 1997, 420:79-85.
102. Sidenius N., Blasi F. Domain 1 of the urokinase receptor (uPAR) is required for uPAR-mediated cell binding to vitronectin. FEBS Lett. 2000, 470:40-46.
103. Sidenius N., et al. Expression of the urokinase plasminogen activator and its receptor in HIV-1-associated central nervous system disease. J. Neuroimmunol. 2004, 157:133-139.
104. Sidenius N., Andolfo A., Fesce R., Blasi F. Urokinase regulates vitronectin binding by controlling urokinase receptor oligomerization. J. Biol. Chem. 2002, 277:27982-27990.
105. Caiolfa V.R., et al. Monomer dimer dynamics and distribution of GPI-anchored uPAR are determined by cell surface protein assemblies. J. Cell Biol. 2007, 179:1067-1082.
106. Bohuslav J., et al. Urokinase plasminogen activator receptor, beta 2-integrins, and Src-kinases within a single receptor complex of human monocytes. J. Exp. Med. 1995, 181:1381-1390.
107. Goodson R.J., Doyle M.V., Kaufman S.E., Rosenberg S. High-affinity urokinase receptor antagonists identified with bacteriophage peptide display. Proc. Natl. Acad. Sci. USA 1994, 91:7129-7133.
108. Wei Y., Lukashev M., Simon D.I., Bodary S.C., Rosenberg S., Doyle M.V., Chapman H.A. Regulation of integrin function by the urokinase receptor. Science 1996, 273:1551-1555.
109. Wei Y., Eble J.A., Wang Z., Kreidberg J.A., Chapman H.A. Urokinase receptors promote beta1 integrin function through interactions with integrin alpha3beta1. Mol. Biol. Cell 2001, 12:2975-2986.
110. Zhang F., Tom C.C., Kugler M.C., Ching T.T., Kreidberg J.A., Wei Y., Chapman H.A. Distinct ligand binding sites in integrin alpha3beta1 regulate matrix adhesion and cell-cell contact. J. Cell Biol. 2003, 163:177-188.
111. Aguirre Ghiso J.A., Kovalski K., Ossowski L. Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling. J. Cell Biol. 1999, 147:89-104.
112. Wei Y., et al. Regulation of alpha5beta1 integrin conformation and function by urokinase receptor binding. J. Cell Biol. 2005, 168:501-511.
113. Degryse B., Resnati M., Czekay R.P., Loskutoff D.J., Blasi F. Domain 2 of the urokinase receptor contains an integrin-interacting epitope with intrinsic signaling activity: generation of a new integrin inhibitor. J. Biol. Chem. 2005, 280:24792-24803.
114. Gargiulo L., et al. Cross-talk between fMLP and vitronectin receptors triggered by urokinase receptor-derived SRSRY peptide. J. Biol. Chem. 2005, 280:25225-25232.
115. Chaurasia P., Aguirre-Ghiso J.A., Liang O.D., Gardsvoll H., Ploug M., Ossowski L. A region in urokinase plasminogen receptor domain III controlling a functional association with alpha5beta1 integrin and tumor growth. J. Biol. Chem. 2006, 281:14852-14863.
116. Wei Y., Tang C.H., Kim Y., Robillard L., Zhang F., Kugler M.C., Chapman H.A. Urokinase receptors are required for alpha5beta1 integrin-mediated signaling in tumor cells. J. Biol. Chem. 2007, 282:3929-3939.
117. Montuori N., Carriero M.V., Salzano S., Rossi G., Ragno P. The cleavage of the urokinase receptor regulates its multiple functions. J. Biol. Chem. 2002, 23:23.
118. Tarui T., et al. Critical role of integrin alpha 5beta 1 in urokinase (uPA)/urokinase receptor (uPAR, CD87) signaling. J. Biol. Chem. 2003, 278:29863-29872.
119. Malengo G., Andolfo A., Sidenius N., Gratton E., Zamai M., Caiolfa V.R. Fluorescence correlation spectroscopy and photon counting histogram on membrane proteins: functional dynamics of the glycosylphosphatidylinositol-anchored urokinase plasminogen activator receptor. J. Biomed. Opt. 2008, 13:031215.
120. Nykjaer A., Conese M., Christensen E.I., Olson D., Cremona O., Gliemann J., Blasi F. Recycling of the urokinase receptor upon internalization of the uPA:serpin complexes. EMBO J. 1997, 16:2610-2620.
121. Cortese K., Sahores M., Madsen C.D., Tacchetti C., Blasi F. Clathrin and LRP-1-independent constitutive endocytosis and recycling of uPAR. PLoS One 2008, 3:e3730.
122. Sahores M., Prinetti A., Chiabrando G., Blasi F., Sonnino S. UPA binding increases UPAR localization to lipid rafts and modifies the receptor microdomain composition. Biochim. Biophys. Acta 2008, 1778:250-259.